RxDoctor Payments Data

Brandon Bonds, MD

Family Medicine · Roseburg, ORNPI 1033406053

Payments from drug & device makers

$570in general payments, 2019–2025

Across 37 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$150
  • GSK$106
  • AbbVie$70
  • Novartis$47
  • AstraZeneca$43
  • Kowa Pharmaceuticals America, Inc.$31
  • plus $124 from 7 others

What the payments were for

  • Food & beverage$55497%
  • Education$163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$570 in reported general payments places this provider in the 80th percentile of 1,221 family medicine providers in Oregon.

See all family medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$16,719
Medicare patients
95
Services billed
201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban147$185,891
XareltoRivaroxaban93$103,748
OzempicSemaglutide68$76,085
JardianceEmpagliflozin44$55,375
TrulicityDulaglutide32$37,966
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$30,406
JanuviaSitagliptin Phosphate23$28,182
Breo ElliptaFluticasone/Vilanterol41$24,366
OxycontinOxycodone Hcl37$19,265
TradjentaLinagliptin16$17,972
MyrbetriqMirabegron15$8,746
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$8,559
Semglee (Yfgn) PenInsulin Glargine-Yfgn17$6,901
Albuterol Sulfate HfaAlbuterol Sulfate144$5,054
Levothyroxine Sodium400$5,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$13$103,74893 claims
Novo NordiskOzempic$150$76,08568 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$106$59,28087 claims
Lilly USA, LLCTrulicity$13$37,96632 claims
Astellas Pharma US IncMyrbetriq$12$8,74615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,221 family medicine providers in Oregon.

Other family medicine in Roseburg

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →